Abstract:

BACKGROUND: Autologous peripheral blood hemopoietic stem cell transplantation (HSCT) in combination with high-dose chemotherapy significantly improves complete remission and survival rate of multiple myeloma patients. However, the relapse rate is high. Bortezomib is 26S proteasomes inhibitor, and effective on the primary treatment of multiple myeloma.

OBJECTIVE: To evaluate the curative effect of HSCT in combination with bortezomib and high dose-melphalan for multiple myeloma.

METHODS: A retrospective analysis of 3 patients with a stage- Ⅲ multiple myeloma admitted to Department of Hematology, Affiliated Hospital of Guiyang Medical College from October 2006 to May 2007, was conducted. Chemotherapy and granulocyte colony-stimulating factor were used to mobilize autologous peripheral blood hemopoietic stem cells. All patients were pretreated with 200 mg/m2 melphalan via intravenous drip 3 days before transplantation, followed by HSCT 48 hours after drug termination.

RESULTS AND CONCLUSION: All patients obtained prompt and sustained hematopoietic reconstitution, and bone marrow depression restored 30 days following HSCT. Case 1 and 2 obtained complete remission, and case 3 obtained partial remission. Results show that HSCT in combination with bortezomib and high-dose melphalan is a safe and feasible treatment on multiple myeloma. The patients have good tolerance to pretreatment.